CHRS FY 2021 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$327M-31.4% YoY

Gross Profit

$269M82.4% margin

Operating Income

-$264M-80.8% margin

Net Income

-$287M-87.9% margin

EPS (Diluted)

$-3.81

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$39M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$679M

Total Liabilities

$582M

Stockholders' Equity

$98M

Cash & Equivalents

$417M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$327M	$476M	-31.4%
Gross Profit	$269M	$438M	-38.6%
Operating Income	-$264M	$156M	-268.8%
Net Income	-$287M	$132M	-317.1%